[Guiding principles for the therapy of severe forms of purulent meningitis (author's transl)].
D000328:Adult; D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D002301:Cardiac Glycosides / Q000627:therapeutic use; D002701:Chloramphenicol / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D005839:Gentamicins / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008581:Meningitis / Q000175:diagnosis / Q000188:drug therapy*; D010406:Penicillins / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants; D002301:Cardiac Glycosides; D004232:Diuretics; D005839:Gentamicins; D010406:Penicillins; D013449:Sulfonamides; D002701:Chloramphenicol; D000667:Ampicillin; D006493:Heparin
Directrices terapéuticas para las graves formas evolutivas de las meningitis purulentas